IllnessBreast cancer / therapy with PARP inhibitors

NGS +

Sanger

Mutations in the BRCA1/2 genes are associated with an increased risk of familial breast or ovarian cancer, but also with a better response to therapy in breast cancer patients. The randomized Phase 3 study OlympiAD evaluated the efficacy and safety of olaparib monotherapy versus chemotherapy of choice in patients with metastatic breast cancer and germline mutations in the BRCA1 or BRCA2 genes. Progression-free survival was increased from 4.2 months (chemotherapy) to 7 months (olaparib) (2). The PARP inhibitor olaparib is approved for the treatment of advanced or metastatic HER2-negative BRCA mutant breast cancer that has previously responded sensitively to platinum-based chemotherapy (1).

References: (1) https://www.dgho.de/aktuelles/news/newsarchiv/2019/olaparib-beim-brcamut-mammakarzinom

(2) https://www.nejm.org/doi/full/10.1056/nejmoa1706450

• Alias: Mamma-Ca (Behandlung mit PARP-Inhibitoren)
• Alias: Mamma-Karzinom (BRCA1, BRCA2); Therapie
• Alias: Olaparib-Therapie
• Breast cancer (BRCA1, BRCA2) - Olaparib therapy